Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo aims to extend remission in aggressive lung cancer

NCT ID NCT07545954

First seen Apr 23, 2026 · Last updated May 21, 2026 · Updated 7 times

Summary

This early-phase study tests whether adding the experimental drug DSP-0390 to the immunotherapy atezolizumab can safely help keep extensive stage small cell lung cancer under control after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen during first-line treatment will receive the combination as maintenance therapy. The main goal is to check safety and side effects, with a secondary look at how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.